 | Up a level |
Berlak, Mareike 
ORCID: 0000-0003-4437-3477, Tucker, Elizabeth ORCID: 0000-0003-3716-6605, Dorel, Mathurin, Winkler, Annika, McGearey, Aleixandria, Rodriguez-Fos, Elias ORCID: 0000-0002-2555-0178, da Costa, Barbara Martins, Barker, Karen, Fyle, Elicia, Calton, Elizabeth, Eising, Selma, Ober, Kim, Hughes, Deborah, Koutroumanidou, Eleni, Carter, Paul, Stankunaite, Reda, Proszek, Paula ORCID: 0000-0002-0780-6790, Jain, Neha ORCID: 0000-0002-8499-3366, Rosswog, Carolina, Dorado-Garcia, Heathcliff, Molenaar, Jan Jasper, Hubank, Mike, Barone, Giuseppe, Anderson, John, Lang, Peter, Deubzer, Hedwig Elisabeth, Kuenkele, Annette, Fischer, Matthias, Eggert, Angelika ORCID: 0000-0003-3476-8184, Kloft, Charlotte, Henssen, Anton George, Boettcher, Michael, Hertwig, Falk, Bluthgen, Nils, Chesler, Louis and Schulte, Johannes Hubertus ORCID: 0000-0003-0671-1201
(2022).
Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.
Mol. Cancer, 21 (1).
LONDON:
BMC.
ISSN 1476-4598
Henssen, Anton ORCID: 0000-0003-1534-778X, Thor, Theresa, Odersky, Andrea, Heukamp, Lukas ORCID: 0000-0002-3388-3482, El-Hindy, Nicolai, Beckers, Anneleen, Slpeleman, Frank, Althoff, Kristina, Schaefers, Simon, Schramm, Alexander ORCID: 0000-0001-7670-7529, Sure, Ulrich, Fleischhack, Gudrun, Eggert, Angelika ORCID: 0000-0003-3476-8184 and Schulte, Johannes Hubertus ORCID: 0000-0003-0671-1201
(2013).
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
Oncotarget, 4 (11).
ORCHARD PARK:
IMPACT JOURNALS LLC.
ISSN 1949-2553